ProfessorIngrid van der Mei

Professor

Menzies Institute for Medical Research

  • Professor
    Menzies Institute for Medical Research
  • Menzies Institute for Medical Research, Menzies Institute for Medical Research, 358b-01 Medical Science 2, Hobart CBD Campuses, TAS

FUNDED PROJECTS

  • GRANT
    FEATURED
    Featured
    Centre of multiple sclerosis research translation
    1 Jul 2024 - 30 Jun 2029
    People funded by this grant:
    • Young K,
    • Taylor B,
    • Reay W,
    • van der Mei I,
    • Zhou Y
    Project Total: $3,000,000; Multiple Sclerosis (MS) is a disease that causes inflammation in the brain. People with MS need treatments that will protect and repair the brain. In our MS Centre, people with MS, researchers, and doctors work together to find out how MS affects the brain. This gives us clues about the type/s of drugs that might help. We grow brain cells in the lab, add the potential drugs, and measure the effect. Drugs that protect brain cells are then tested in the clinic to see how they help people with MS. Funded by: National Health & Medical Research CouncilNational Health & Medical Research Council - Grant-Centre of Research Excellence ($6,000,000); University of Tasmania ($177,384).
  • GRANT
    FEATURED
    Featured
    Improving outcomes for people with MS through digital technologies
    1 Jan 2022 - 31 Dec 2026
    People funded by this grant:
    • van der Mei I
    Project Total: $650,000; The health-related quality of life in people with MS is substantially lower than the Australian population. My vision is to harness digital health technologies with the aim of improving both clinical care and self care. I am developing a digital patient-centred health care system (InforMS), an online intervention (MS WorkSmart), a symptom tracker App (My SymptoMS) and four short specialist Massive Open Online Courses. I will assess the impacts on behaviour change, health outcomes and clinical care. Funded by: Multiple Sclerosis Australia - Fellowship-Senior ($650,000); University of Tasmania ($460,751).
  • GRANT
    FEATURED
    Featured
    InforMS - an electronic patient-driven health care model with digital biomarker monitoring that improves the clinical care of people with MS
    1 Oct 2020 - 30 Sep 2027
    People funded by this grant:
    • van der Mei I,
    • Butzkueven H,
    • Taylor B,
    • Palmer A,
    • Blizzard L
    Project Total: $1,167,815; Multiple Sclerosis (MS) is a high cost and high burden neurological disease. Problem: there are many disease-modifying therapies available, so clinicians can theoretically switch treatments rapidly based on disease activity and side-effects. Yet this proves difficult when data on these is infrequently collected (currently 1-2 times a year) and is insensitive to fluctuations between visits. Solution: modern computing technologies (mobile apps, wearables) are changing the way health is monitored throughout medicine. We are enabled to collect more data, more accurately, and more frequently, and to share it more easily. If we could effectively harness such new monitoring technologies for MS, clinicians could be supported with objective, prospectively collected, frequently measured, change-sensitive data. Proposed research: we will create an electronic patient-centred health care system, InforMS, that becomes a one-stop-shop? management system for people with MS. It visualises patient-reported data, allows daily tracking and uploading of data from smartphones and wearable sensors, and allows sharing with clinicians via print, email, third-party access and via MSBase: the most widely used clinician registry worldwide. For clinical care, it would (1) enable timelier changes to treatments, and (2) provide greater confidence that treatments work. For patient self care, it would (3) empower people with MS to take a central role in managing their disease, and (4) activate them to collect novel time-sensitive data. For research, it would (5) deliver powerful annual trend data to enhance MS research. This is a paradigm shift in MS care and research. We already have a prototype of InforMS, developed together with end-users. In this proposal, we will add several key functionalities, roll out the full InforMS system within a registry of ~3,000 people with MS, and follow participants over time to test and optimise the system in practice. Funded by: National Health & Medical Research CouncilNational Health & Medical Research Council - Grant-Partnership Project ($1,535,630); Multiple Sclerosis Research Australia Ltd ($400,000); University of Tasmania.
  • CONSULTANCY/CONTRACT RESEARCH
    FEATURED
    Featured
    Australian MS Longitudinal study
    1 Jan 2014 - 30 Jun 2029
    People funded by this grant:
    • van der Mei I,
    • Taylor B,
    • Palmer A,
    • Laslett L,
    • Campbell J
    Project Total: $2,373,061; The main objectives of this project are: a) to continue the established multi-disciplinary research database for Australia with MS that will provide answers to important questions about the disease that are not able to be addressed by projects funded in the normal, relatively short cycle of research grants; b) to encourage nationwide (and international) multi-disciplinary collaboration on MS research projects, utilising valid and reliable measures that are internationally accepted and compatible wherever possible, and to lead by example in the unification of Australia's efforts to solve the various problems associated with MS; c) to reduce the cost of multi-disciplinary research on MS by provision of a large, well-characterised cohort of volunteer subjects for future studies. Funded by: Multiple Sclerosis Australia ($2,354,730); University of Tasmania.
  • GRANT
    Feasibility and acceptability of activity monitors and symptom tracker apps
    1 Aug 2025 - 31 Jul 2027
    People funded by this grant:
    • Laslett L,
    • van der Mei I,
    • Taylor B,
    • Honan C,
    • Bramich S
    Project Total: $24,999; Poor sleep is common in the community, but even more common in people living with MS. Poor sleep has serious impacts on health, including clinically important reductions in quality of life. Treatments to improve symptoms and sleep are urgently needed in people living with MS. To do that, we need to assess sleep in a better way than we do now. This research program will use activity monitors to investigate whether using activity monitors 24/7 for up to 21 days and daily assessment of MS symptoms using the My Symptoms app for up to 21 days is feasible and acceptable, what the shortest duration of assessment is that will still give good quality data, and whether we can predict who will not want to use actigraphs and symptom trackers, and, when used, whether they provide better data on sleep, over and above that captured by standard questionnaires. We will use learnings to plan and appropriately power future clinical trials for sleep in people living with MS. Funded by: Multiple Sclerosis Australia - Grant-Incubator ($24,335); University of Tasmania.
  • UTAS INTERNAL FUNDING
    Multiple Sclerosis and Mental Health: A prioritisation of treatment needs and preferences.
    21 Mar 2025 - 31 Dec 2025
    People funded by this grant:
    • Emery H,
    • Honan C,
    • van der Mei I
    Project Total: $5,000; MS is a chronic neurodegenerative condition that can impact psychological, social, cognitive, and physical functioning. Despite advances in healthcare and occupational rehabilitation, people with MS often experience ongoing difficulties across their professional and personal lives, which then impact their mental health. Compared to the general population, people with MS have a higher prevalence rate of anxiety, depression, substance abuse, bipolar, suicidality, and psychosis. Despite the need for effective and timely psychological interventions, there remains a lack of consensus on the best treatment approaches to improve the mental health of people with MS. Importantly, prior to evaluating the current evidence-base, there is a need to establish what outcomes are most critical to determine intervention effectiveness. To determine this, the engagement of people with lived experience and those who support them is vital, particularly as recent research suggests that intervention outcomes often do not coincide with the preferences of people with MS. Establishing the priorities of people with MS, those who support them, and healthcare professionals for mental health care is the primary objective of the current priority setting project. This project will adhere to best practice approaches for research engagement with consumers and priority setting methodologies. Using principles of co-design, we will develop a priority setting survey to ascertain the mental health priorities of Australians living with MS. This will include the identification of outcomes considered critical to people with MS when evaluating the effectiveness or benefit of mental health interventions. In addition to this, we will also collect invaluable information relating to which aspects of mental health are most important to people with MS, factors that impact experiences engaging with mental health professionals, and areas for special consideration when delivering mental health interventions in this population. Funded by: Professor Michelle Craske Early Career Research Grant; University of Tasmania ($7,602).
  • GRANT
    The double burden of wage discrimination for marginalised groups with MS
    1 Jan 2025 - 30 Jun 2026
    People funded by this grant:
    • Campbell J,
    • van der Mei I,
    • Taylor B,
    • Kamal M,
    • Blacklow P
    Project Total: $24,833; Employment provides substantial socioeconomic benefits to an individual by granting access to economic resources, fostering social networks, offering opportunities to develop life skills, and promoting a sense of self-worth. There is a positive association between employment, quality of life and life satisfaction for people living with disability. The health economic impact of MS is high costing Australian society over $2.5 billion per year. There are also significant quality of life impacts for families, carers and supporters. As MS-related disability severity increases the health and economic burden of MS increases significantly. To illustrate, as disability severity increases from no to severe MS-related disability, the cost to Australian society is 270% higher ($32,000 to $125,000 per year per person living with MS) Importantly, these estimates are likely underestimates. There are many inputs to the economic equation that need to be explored including the level of wage discrimination for people living with MS in Australia and how this wage discrimination is likely increased as disability severity increases for people who remain in the workforce (particularly as people transition from no to mild and moderate disability). A notable characteristic of MS is its disproportionate effect on women, with a female-to-male prevalence ratio reaching as high as 3:1. The existing literature has shown that gender discrimination continues to exist in the labour market in various stages, from recruitment to promotion. Previous work has also shown that women face a double burden in the labour market in the presence of intersectionality of gender and disability or other health-related problems. This is also revealed for people who identify as non-binary. Therefore, we aim to evaluate if the association between living with MS and income differs according to gender in Australia and if labour market discrimination can be identified as a potential source for such outcomes. Funded by: Multiple Sclerosis Australia - Grant-Incubator ($24,833); University of Tasmania.
  • CONSULTANCY/CONTRACT RESEARCH
    MS Trial Screen
    1 Jul 2024 - 30 Jun 2027
    People funded by this grant:
    • van der Mei I,
    • Laslett L
    Project Total: $160,615; MS Trial Screen is a platform that will act as a one-stop-shop for Australians living with MS who want to register and access cutting edge clinical trials. Using a secure internet-based portal accessible from any internet-enabled device, consumers will be able to register and determine if they meet criteria for clinical trials currently recruiting in Australia. Funded by: Multiple Sclerosis Australia ($160,615); University of Tasmania.
  • GRANT
    Investigating the double burden of wage discrimination for women and marginalised groups living with Multiple Sclerosis
    13 Jun 2024 - 31 Dec 2024
    People funded by this grant:
    • Campbell J,
    • Kamal M,
    • van der Mei I,
    • Taylor B,
    • Blacklow P
    Project Total: $27,500; MS costs Australia over $2.5Billion per year, however, this is likely an underestimate. There are many inputs to the economic equation that need to be explored including the level of wage discrimination for people living with MS in Australia, particularly women and marginalised groups, and how this wage discrimination is likely increased as disability severity increases for people who remain in the workforce (particularly for people who transition from no, to mild and moderate disability). Overall, we aim to evaluate if the association between multiple sclerosis and earnings (including income) differs from a wage discrimination perspective according to gender in Australia. We hypothesise that there is a double burden, especially as MS-related disability increases. Funded by: Donation via Menzies Institute for Medical Research - Donation ($27,500); University of Tasmania.
  • GRANT
    Understanding how Epstein-Barr virus and other factors program multiple sclerosis onset and progression through epigenetic pathways to inform prevention and treatment with risk stratification
    1 Jul 2023 - 30 Jun 2027
    People funded by this grant:
    • Ponsonby A-L,
    • van der Mei I,
    • Saul A,
    • Taylor B
    Project Total: $1,783,892; Multiple sclerosis (MS) is an inflammatory and degenerative disease of the central nervous system (CNS) where onset and progression are multifactorial, associated with both environmental and genetic factors. These factors likely act, at least in part, through epigenetic alteration, a modifiable mechanism of gene regulation. DNA methylation is a well-characterised epigenetic mechanism that can be measured in large human studies. This potential for new insights is further strengthened by conducting molecular profiling of Epstein-Barr virus (EBV) and associated host immune responses. We have assembled epidemiological studies that have the capacity to be highly dimensioned with regard to multifactorial indices that underlie disease onset and progression the Ausimmune study, the AusLong study, and the PrevANZ trial. We will characterise how immune responses to viral infections trigger autoimmune diseases in some individuals with an emphasis on (i) EBV antibodies that target CNS proteins (Aim 1) to (ii) epigenetic programming (Aim 2), (iii) the interplay between key MS-associated herpesviruses including EBV (Aim 3), and (iv) the response to disease-modifying therapy depending on insular and short-term clinical characteristics like the patients EBV profile (Aim 4). These results will be extrapolated to inform development of treatments for MS, modelled on similar treatments used in EBV-linked lymphoproliferative disease, to translate into prevention and treatment. We will generate knowledge that supports risk stratification so individuals can reduce their probability of (i) developing autoimmune disease or (ii) utilise optimal therapies to slow disease progression. In this way we will not be able to provide updated personalised prevention and treatment advice for people at risk of or with MS, based on their genetic, epigenetic, and environmental profiles. (If successful, this will appear on your staff profile page) Funded by: Medical Research Future Fund - Grant - Multiple Sclerosis Research; University of Melbourne; University of Tasmania.
  • UTAS INTERNAL FUNDING
    The feasibility of using wearable devices to assessing sleep and a symptom tracker app to assess MS symptoms in Tasmanians living with multiple sclerosis
    2 May 2023 - 31 Oct 2023
    People funded by this grant:
    • Laslett L,
    • van der Mei I,
    • Taylor B,
    • Honan C,
    • Bramich S
    Project Total: $16,000; Multiple sclerosis (MS) is an autoimmune disorder of the central nervous system. While MS remains rare, MS is more common in Tasmania (per capita) than elsewhere in Australia(1). Poor sleep is common in the community and even more common in people with MS (pwMS) (2) and include insomnia, sleep apnoea, and restless leg syndrome(3-8). A recent paper from CIs Laslett, van der Mei, Taylor and Honan demonstrates that two thirds of Australians with MS have sleep quality in the clinically poor range(2). We showed poor sleep is strongly associated with worse health related quality of life independent of MS symptoms and obesity(2). Deficits in quality of life due to poor sleep are in the clinically relevant range. By attempting to understand dysfunctional sleep in MS we have an opportunity to improve quality of life and make a difference in the lives of people with MS. To demonstrate we can use activity monitors to collect sleep data (24/7, 7-14 days). Demonstrate that using the My SymptoMS app daily is acceptable to pwMS. Evaluate the optimal duration by which activity monitors should be used to reliably measure sleep in pwMS without overburdening participants (7 vs 14 days). Validate sleep data from My SymptoMS compared to data from activity monitors and questionnaires. Investigate associations between activity-monitor assessed outcomes and quality of life, and symptoms using the My SymptoMS app. Funded by: Menzies Institute for Medical Research; University of Tasmania ($16,000).
  • CONSULTANCY/CONTRACT RESEARCH
    Economic Impact report 2023
    1 Jan 2023 - 31 Dec 2025
    People funded by this grant:
    • van der Mei I,
    • Palmer A,
    • Campbell J,
    • Taylor B,
    • Zhao T
    Project Total: $184,175; To produce a Report on the Economic Impact of MS in Australia in that: A brief overview of MS Prevalence of MS Healthcare costs and indirect costs (including lost productivity) Quality of life for those affected by MS Funded by: Multiple Sclerosis Australia ($184,175); University of Tasmania.
  • GRANT
    Evaluating the factors influencing National Disability Insurance Scheme participation and its impact among Australians with MS
    1 Jan 2023 - 31 Dec 2025
    People funded by this grant:
    • Taylor B,
    • Claflin S,
    • van der Mei I,
    • Lechner-Scott J,
    • Campbell J
    Project Total: $244,123; This project will evaluate the roll out of the National Disability Insurance Scheme (NDIS) among Australian living with MS. We will investigate factors associated with NDIS participation and, among participants, NDIS plan value. In order to do this, we will conduct a several studies, including a retrospective cohort study in a representative group of Australians living with MS. Funded by: Multiple Sclerosis Australia - Grant-Project ($244,123); University of Tasmania.
  • GRANT
    The role of pain in MS
    1 Jan 2023 - 31 Dec 2025
    People funded by this grant:
    • Saul A,
    • van der Mei I
    Project Total: $225,000; Pain is prevalent in Multiple Sclerosis (MS), yet there is uncertainty of the nature of MS-related pain, how pain fluctuates over time in the short and long term, and how it relates to other symptoms of MS. While pain has a substantial impact on people with MS (PwMS), only few studies have separated the different types of pain that PwMS experience. Pain is commonly treated in MS, but low levels of relief have been reported. This program of work will focus on understanding pain in MS by examining specific types of pain, in terms of prevalence, severity, predictability and its chronic nature. Pain management experiences will be examined by identifying which pharmacological and non-pharmacological treatments are most frequently used, and which have the highest perceived effectiveness. This work will focus on how pain relates to other symptoms of MS and how it fluctuates in the short-term (during the day) and long term (multiple years). The project is designed to improve the understanding on individual types of pain of PwMS, to develop advice on pain management for PwMS and health practitioners, and to design treatment intervention studies for specific types of pain. Funded by: Multiple Sclerosis Australia - Fellowship-Postdoctoral ($225,000); University of Tasmania ($121,848).
  • GRANT
    AMSLS COVID-19 Registry
    18 May 2020 - 17 May 2021
    People funded by this grant:
    • van der Mei I
    Project Total: $30,562; The Australian MS Longitudinal Study will run surveys on COVID-19 and MS as part of the COVID-19 and MS Global Data Sharing Initiative. This data will be uploaded to a central database together with other MS registries around the world. The data will identify whether people with MS have a higher risk of having COVID-19, whether the disease is more severe and whether disease modifying therapies are impacting the disease. Funded by: Multiple Sclerosis Australia - Grant - Grant-in-Aid ($30,562); University of Tasmania.
  • CONSULTANCY/CONTRACT RESEARCH
    MS Nurses Survey and analysis
    1 Jan 2020 - 30 Apr 2021
    People funded by this grant:
    • van der Mei I,
    • Taylor B
    Project Total: $24,118; 1. Describe the patterns of access to an MS Nurse of Australians with MS (percentage of access to an MS Nurse overall and by subgroups such as state and remoteness and MS type; reasons no access; frequency that has an MS Nurse as part of their care; provider model; types of access and frequency last 12 months; types of MS Nurse care received) 2. Describe the perceived effects of MS Nurse care in terms of adherence to MS treatments, changes to management of MS symptoms and side effects, changes towards a healthier lifestyle, and rating on overall value. 3. Examine whether people with MS who have access to an MS Nurse have better disease outcomes, employment outcomes and enhanced quality of life compared to those not having access to an MS Nurse, and examine whether these differences remain after taking into account personal and clinical characteristics (e.g. education level, onset type). 4. Examine whether people with MS who have access to an MS Nurse have better lifestyle characteristics (e.g. physical activity level), and fewer comorbidities, and examine whether these differences remain after taking into account personal and clinical characteristics (e.g. education level, onset type). Funded by: Multiple Sclerosis Australia ($24,118); University of Tasmania.
  • GRANT
    The Menzies Multiple Sclerosis Flagship Program
    1 Jan 2020 - 30 Jun 2024
    People funded by this grant:
    • Taylor B,
    • Young K,
    • Charlesworth J,
    • van der Mei I,
    • Palmer A
    Project Total: $10,000,000; The Menzies Institute for Medical Research Multiple Sclerosis Flagship Program (MS Flagship) leverages the unique critical mass of MS research in Tasmania connected with Australian MS researchers, collaborators, MS societies and people with MS to address the gaps in the assessment, diagnosis and treatment of MS. Our work builds on our well-developed collaborations and laboratory, epidemiological, health economics and clinical research platforms. Our aim is to improve the clinical management of MS by slowing, halting and even reversing the rate of MS disease progression and to improve the quality of life and reduce the impact that MS has on individuals, their families and society. This project will expand the scope of the MS Flagship program and accelerate discoveries in MS research by supporting five key Activities: 1. Establish 'MS Stem' - a stem cell bank specifically designed to advance MS research 2. Gain a better understanding of the regeneration of brain cells and myelin repair 3. Expand our understanding of the rare genetic variation underpinning MS using genome sequencing of MS families and 'MS Stem' cell bank samples 4. Develop a treatment economic model which can identify cost-effective treatments and interventions for MS 5. Develop education tools and online resources, including an App specifically for people living with MS Funded by: Medical Research Future Fund - Grant - Accelerated Research ($10,000,000); University of Tasmania.
  • CONSULTANCY/CONTRACT RESEARCH
    Impact of remoteness on MS outcomes
    1 Jan 2019 - 31 Dec 2020
    People funded by this grant:
    • van der Mei I,
    • Palmer A,
    • Taylor B
    Project Total: $49,999; * Do people with MS living in regional or remote areas have worse disease outcomes, employment outcomes and quality of life compared to those living in major cities? * How are the costs of MS different for those living in regional or remote areas compared to those living in major cities? * Are any of the above differences explained by personal characteristics (e.g. lower education level), clinical characteristics (e.g. primary progressive onset type), lifestyle characteristics (e.g. lower physical activity level), comorbidities, DMT use, or lack of social support. Funded by: Multiple Sclerosis Australia ($49,999); University of Tasmania.
  • GRANT
    Understanding the role of diet in Multiple Sclerosis
    1 Jan 2019 - 31 Mar 2023
    People funded by this grant:
    • Saul A,
    • van der Mei I
    Project Total: $91,000; Many people with Multiple Sclerosis (MS) modify their dietary intake or use MS-specific diets, but there is a low evidence base that different aspects of dietary intake has an effect on disease activity, progression and MS-specific symptoms. I will reduce this knowledge gap by examining the role of diet in MS using the AusLong study - an NHMRC funded and internationally unique cohort of people who were originally diagnosed with a first clinical diagnosis of demyelination and have been followed annually for 10 years. I will examine whether dietary patterns and indices of diet quality and inflammation are associated with relapses, disability progression, Magnetic Resonance Imaging outcomes, fatigue, anxiety, and depression. This knowledge is essential in order to provide dietary advice to MS patients to enhance quality of life and to design diets that could be tested in a randomised controlled trial setting. Funded by: Multiple Sclerosis Australia - Scholarship-Postgraduate ($91,000); University of Tasmania.
  • GRANT
    Identifying epigenetic factors involved in MS onset : utilising population-based studies with genetic and environmental measures
    10 Jan 2018 - 10 Jan 2021
    People funded by this grant:
    • Ponsonby A,
    • Scott R,
    • Lucas R,
    • Lea R,
    • Taylor B
    Project Total: $851,451; Multiple Sclerosis (MS) is an inflammatory and degenerative disease of the central nervous system (CNS) whose onset is associated with both environmental and genetic factors. These factors likely act, at least in part, through epigenetic alteration, a modifiable mechanism of gene regulation. DNA methylation is a well characterized epigenetic mechanism that can be evaluated at the genome-wide level with the aid of high throughput scanning technologies. Studies of MS patients at disease onset that include epigenetic factors in conjunction with genetic and environmental factors will provide new insights into disease etiology and thus guide better preventive and treatment strategies. This proposal is to undertake a whole epigenomewide study in a multi-site case control study (with replication in other international studies using similar methods). Funded by: National Multiple Sclerosis Society - Grant-Research; University of Tasmania.
  • GRANT
    Multiple Sclerosis (MS) WorkSmart program: A novel online program to assist people living with MS in the workforce
    1 Jan 2018 - 1 Feb 2021
    People funded by this grant:
    • van der Mei I,
    • Scott J,
    • de Salas K,
    • Honan C,
    • Taylor B
    Project Total: $300,000; Nearly half ($494M) of the total cost of Multiple Sclerosis (MS) ($1.04 billion a year) in Australia is due to sickness absence and early retirement. A large societal cost saving can be made by assisting people with MS to maintain their employment and reduce difficulties associated with their employment. Further, this will have financial benefits for people with MS, as well as improve their overall quality of life. Despite a clear need, there are currently no self-management interventions specifically for people with MS in the workforce. In this project we propose to complete the development and undertake a feasibility study of the MS WorkSmart Program. MS WorkSmart is an online cognitive behaviour therapy self-management program with telephone support accessible on different devices. MS WorkSmart guides a person with MS through six modules over 13-15 weeks, using quizzes, videos and homework? activities to assist the learning of strategies that can be applied to their working and daily lives for optimal MS management. The program is being developed together with people with MS and other stakeholders using focus groups and iterative feedback. It is underpinned by cognitive behavioural theory, is embedded in the literature and specifically designed for people with MS who are in the workforce. People will be assisted with telephone-delivered psychological support. Funded by: IOOF Foundation - Donation ($300,000); University of Tasmania.
  • GRANT
    Select Foundation Senior Research Fellowship -MS Flagship
    1 Jan 2018 - 31 Dec 2021
    People funded by this grant:
    • van der Mei I
    Project Total: $437,500; Funded by: The Select Foundation - Fellowship-Senior Research ($437,500); University of Tasmania.
  • CONSULTANCY/CONTRACT RESEARCH
    Understanding MS MOOC (Massive Open Online Course)
    1 Jan 2018 - 31 Dec 2022
    People funded by this grant:
    • Taylor B,
    • Claflin S,
    • van der Mei I
    Project Total: $506,000; Developing a massive open online course to improve the overall knowledge of MS in the wider MS community including those living with MS, their families and carers, as well as health care professionals, based on the hypothesis: 'Providing current, evidence-based information about MS will increase the knowledge and health literacy of course participants, resulting in improved outcomes for those living with MS and a greater understanding of MS in the general population?. Funded by: MS Plus ($306,000); The Select Foundation ($200,000); University of Tasmania ($215,796).
  • CONSULTANCY/CONTRACT RESEARCH
    WorkSmart Project
    1 Jan 2018 - 31 Dec 2019
    People funded by this grant:
    • van der Mei I,
    • Scott J,
    • de Salas K
    Project Total: $100,000; Nearly half ($494M) of the total cost of Multiple Sclerosis (MS) ($1.04 billion a year) in Australia is due to sickness absence and early retirement. A large societal cost saving can be made by assisting people with MS to maintain their employment and reduce difficulties associated with their employment. Further, this will have financial benefits for people with MS, as well as improve their overall quality of life. Despite a clear need, there are currently no self-management interventions specifically for people with MS in the workforce. In this project we propose to complete the development and undertake a feasibility study of the MS WorkSmart Program. MS WorkSmart is an online cognitive behaviour therapy selfmanagement program with telephone support accessible on different devices. MS WorkSmart guides a person with MS through six modules over 13-15 weeks, using quizzes, videos and homework? activities to assist the learning of strategies that can be applied to their working and daily lives for optimal MS management. The program is being developed together with people with MS and other stakeholders using focus groups and iterative feedback. It is underpinned by cognitive behavioural theory, is embedded in the literature and specifically designed for people with MS who are in the workforce. People will be assisted with telephone-delivered psychological support. In this project we will develop the online intervention and conduct a feasibility study on 40 people with MS. The feasibility study will address key elements that are essential prior to conducting a fully powered randomised controlled trial Funded by: MSWA ($100,000); University of Tasmania.
  • CONSULTANCY/CONTRACT RESEARCH
    Economic Impact of MS - 2007 cost of illness data AMSLS - PPMS sub-analysis
    1 Jan 2017 - 31 Dec 2017
    People funded by this grant:
    • van der Mei I,
    • Palmer A,
    • Taylor B
    Project Total: $49,379; Based on the published report 'Economic Impact of Multiple Sclerosis in 2010 - Australian MS Longitudinal Study (AMSLS)' Roche is interested in cost and utility data collected from patients with primary progressive multiple sclerosis (PPMS) only. Despite the type of MS not specifically being captured in the 2007 Cost Diary, 39 people with PPMS could be identified by matching participants with a more recent data collection. Roche is seeking Australian, PPMS-specific cost and utility data to inform a PBAC submission lodged in March 2017. A sub-analysis of the data presented in the 2010 report for PPMS patients only was identified as a viable data source to inform the PBAC submission. Objective * PPMS-specific cost and utility data from the 2010 AMSLS analysis (2007 Cost Diary) categorised for applicability in a PBAC submission. * Cost and utility data reported per EDSS * Results available six weeks from the date of the fully signed contract. Funded by: Roche Products Pty Ltd ($49,379); University of Tasmania.